Real-Time intelligence That Drives Confident Decisions
EpiLansis is a next-gen, AI-powered cloud platform designed to simplify and accelerate epidemiology research and market forecasting. The platform unifies global epidemiology intelligence, patient journey analytics, disease burden insights, and competitive and treatment landscapes — all within a single, integrated environment.
Built for clinical, commercial, and strategic decision-makers, EpiLansis transforms complex epidemiology data into clear, decision-ready intelligence — helping teams prioritize pipelines, design smarter launch strategies, and forecast market potential with greater accuracy.
20+
Therapy areas
450+
Indications
30+
Countries
47,000+
PMR touchpoints
18,000+
KOL & payer insights
How EpiLansis Supports Your Success
Bridge the gap between fragmented data and actionable insights with our comprehensive epidemiology and market access intelligence
Problem
- Data is still fragmented, inconsistent, or slow to update
- Rising complexity of sub-populations & targeted therapies
- Difficult to access accurate patient funnel across geographies
- Multiple data sources, inconsistent methodology, lack of real-time insights
Solution
- 100% Transparent & Fully Traceable Data
- Global Coverage Across 30+ Markets
- Deep Granularity of Data
- Continuous Update with Market Dynamics
- Customizable Outputs - Interactive Dashboards, Detailed Reports, or Data Exports
Outcomes
- Research timelines from weeks to minutes
- Validated patient pool size, disease burden, and unmet needs
- Identify high-value indications and prioritize assets with stronger market potential
- Pinpoint high-burden geographies and optimize launch sequencing
Why Teams Choose EpiLansis
A comprehensive suite of intelligence tools designed to navigate the entire product lifecycle—from initial epidemiology to strategic market planning.
Client Reviews
Trusted by global pharmaceutical leaders to deliver precision in patient share estimations and therapeutic benchmarking.
“Support on current drug utilizations and benchmarking of emerging therapy, greatly helped us in narrowing down on patient share estimations for internal calculations ״
Santen PharmaDirector
“Patient share for approved therapies are estimated perfectly. Indeed it's great pieces of work. I liked the way segmentation was shown and patient flow was discussed״
Vicore PharmaDirector
“Happy to read the market insight report, really informative and applied to build marketing strategy״
NewronDirector
“This is the first time I worked with Thelansis, I could say the team is truly professional, Cheers guys ״
SanquinDirector
“ We want to congratulate team Thelansis for their continuous support during this tough time ״
WEX TherapeuticsDirector
"We are really fortunate to interact with Thelansis' Forecasting team, well seasoned professionals who understand what's the actual need "
Reata PharmaceuticalsVice President
" We are really fortunate to interact with Thelansis' Forecasting team, well seasoned professionals who understand what's the actual need "
Stemline TherapeuticsVice President- Marketing
"Some great piece of patient based forecast model; and market assumptions. Tying up beautifully with the payer's insights "
CamurusDirector
"Liked the way the outcome was structured. Regulatory assessment was spot-on. Country-wise regulatory scenarios were gold to us at this point"
Asarina PharmaDirector
"Satisfied with the companies core competency around Clinical Trial Outcome analysi"
Acadia PharmaceuticalsDirector
How Epilansis Drives Market Success
By providing a comprehensive view of each indication and its true market potential
Using its advanced analytics engine, EpiLansis evaluates patient populations, treatment adoption patterns, and regional epidemiology variations across global markets. This enables teams to quickly quantify addressable patient pools, identify unmet needs, and assess opportunities across different therapy areas.
The platform also supports strategic planning by modeling patient funnels, forecasting market potential, and highlighting high-value geographic markets and niche patient segments. With continuously updated epidemiology data and interactive insights, EpiLansis empowers biopharma, consulting, and strategy teams to prioritize pipelines, refine launch strategies, and make data-driven investment decisions with greater confidence.
An oncology strategy team exploring a rare sub-indication can quickly validate whether the opportunity is worth deeper investigation. EpiLansis enables teams to estimate addressable patient populations using incidence, prevalence, and stage-specific segmentation across key markets. It highlights gaps in the diagnostic funnel, treatment eligibility, and regional variations in patient identification. This allows teams to assess clinical trial feasibility, prioritize geographies, and identify unmet needs before committing to extensive research.
For chronic neurodegenerative diseases, EpiLansis helps teams understand the real-world complexity of patient populations. The platform highlights gender distribution differences, age clustering, comorbidity burden, biomarker testing rates, and diagnosis delays across markets. It also maps the diagnostic funnel to reveal where patients drop off before reaching treatment. These insights support more accurate patient funnel modeling, clinical trial feasibility planning, and better alignment of medical strategies with real patient pathways.
Metabolic disorders often show very different epidemiology patterns across regions. EpiLansis allows teams to compare prevalence drivers, diagnosis rates, and treatment adoption across global markets. For example, disease burden in North America may be linked to lifestyle risk factors, while APAC patterns may reflect genetic predisposition and screening gaps. These insights help teams design localized commercial strategies, prioritize markets, and align launch planning with regional healthcare dynamics.
Ready to Transform Data into Decision-Ready Intelligence?
Join the next generation of life science leaders using AI-powered epidemiology to de-risk their pipelines and master market forecasting.